Mizutamari RK, Wiegandt H and Nores GA
"Characterization of anti-gangliosides antibodies present in normal human plasma" (1994) J. Neuroimmunol. 50 , 215-220.

Kremer DM, López PHH, Mizutamari RK, Bacile EA and Nores GA
"Factors affecting glycolipid recognition by antibodies: density-dependent binding of anti-GD1a polyclonal IgG from a neurological patient" (1997) J. Neurosc. Res. 47 , 636-641.

Mizutamari RK, Kremer RJ, Bacile EA and Nores GA
"Anti-GM1 IgM-antibodies present in human plasma: affinity and biological activity changes in a patient with neuropathy"(1998) J. Neurosc. Res. 51 , 237-242.

Lopez PHH, Irazoqui FJ and Nores GA
"Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies" (2000) J. Neuroimmunol., 105 , 179-183.

Lopez PHH, , Lardone RD, Irazoqui FJ, Villa AM, Di Egidio M, Saizar RD, Sica REP and Nores GA
“Variable patterns of anti-GM1 IgM-antibody population defined by affinity and specificity in patients with motor syndromes.” (2001) J. Neuroimmunol. 119 , 131-136.

Lopez PHH, Lardone RD, Irazoqui FJ, Maccioni M and Nores GA
“The origen of anti-GM1 antibodies in neuropathies: The “binding site drift” hypothesis (Review)”. (2002) Neurochem. Res. 27 , 687-695.

Lopez PHH, Villa A, Sica REP and Nores GA
“High affinity as a disease associated factor in anti-GM1 antibodies: comparative characterization of experimentally produced vs. disease-associated antibodies”. (2003) J. Neuroimmunol. 128 , 69-76.

Alaniz ME, Lardone RD, Yudowski SL, Farace MI and Nores GA
“Normally occurring human anti-GM1 antibodies are part of the immune response to bacteria” (2004) Infect. Immun. 73 , 2148-2151.